Comparison of constitutional and dermatologic side effects between COVID-19 and non–COVID-19 vaccines: Review of a publicly available database of vaccine side effects

Cohen, Stephanie R.; Gao, David X.; Kahn, Jared S.; Rosmarin, David

doi:10.1016/j.jaad.2021.09.044

Cited by 6 publications

(9 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the top twenty oral AEs, oral paresthesia was most reported after COVID-19 and seasonal influenza vaccination (14 and 16%, respectively), followed by lip swelling (12 and 20%), ageusia (12 and 5%), oral hypoesthesia (11 and 14%), swollen tongue (10 and 7%), dysgeusia (10 and 8%), taste disorder (5 and 4%), dry mouth (5 and 1%), and oral herpes (3 and 3%). Cohen et al found that constitutional AEs such as headache, fatigue, and pyrexia had a significantly higher prevalence following COVID-19 than seasonal influenza and hepatitis B vaccines in the VAERS database ( 9 ). Likewise, a recent comprehensive analysis of the US and European Union surveillance systems indicated that the largest absolute risks following COVID-19 vaccines were constitutional, dermatological, neurological and gastrointestinal AEs ( 10 ).…”

Section: Discussionmentioning

confidence: 99%

Oral Adverse Events Following COVID-19 Vaccination: Analysis of VAERS Reports

Riad

Põld

Kateeb

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

BackgroundOral adverse events (AEs) following COVID-19 vaccination have been sporadically reported during the previous months, warranting further investigation for their prevalence and suspected relationship with vaccine-elicited immune response.MethodsA retrospective analysis using the Vaccine Adverse Event Reporting System (VAERS) data was conducted to evaluate AEs within the oral cavity (mucosa, tongue, lips, palate, dentition, salivary glands) and AEs involving taste and other sensations. Oral AEs reported after receiving COVID-19 vaccination (test group) and seasonal influenza vaccination (control group) were extracted and cross-tabulated to assess their relative prevalence.ResultsAmong the 128 solicited (suspected) oral AEs, oral paresthesia (0.872%) was most reported after receiving COVID-19 vaccines, followed by the swelling of lips (0.844%), ageusia (0.722%), oral hypoesthesia (0.648%), swollen tongue (0.628%), and dysgeusia (0.617%). The reported prevalence of oral AEs was higher in the COVID-19 vaccine group than in the seasonal influenza group. The distribution pattern of the most reported oral AEs was similar for both COVID-19 and seasonal influenza vaccines. Female sex, older age (>39 years old), primer doses, and mRNA-based COVID-19 vaccines exhibited a higher reported prevalence of oral AEs.ConclusionWithin the limitations of this study, COVID-19 vaccines were found to be associated with rare oral AEs that are predominantly similar to those emerging following seasonal influenza vaccines. The most commonly reported oral AEs were oral paraesthesia (mouth-tingling), lip swelling, and ageusia, representing various pathophysiologic pathways that remain unclear. Taste-related AEs should be acknowledged in the context of the COVID-19 pandemic and the public should be adequately informed about a potential taste dysfunction after receiving the COVID-19 vaccination. Dentists and dental teams need to be aware of the prevalence, severity, and prognosis of oral AEs to inform their patients and increase public confidence in vaccines.

show abstract

Section: Discussionmentioning

confidence: 99%

Oral Adverse Events Following COVID-19 Vaccination: Analysis of VAERS Reports

Riad

Põld

Kateeb

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…People generally imaged the vaccines to resemble influenza vaccines, and were not aware that influenza vaccination can cause side effects. However, since the CIOVID-19 vaccine has a higher rate of side effects than conventional vaccines [26], they realized that it was completely different experience. They felt even more anxious before their vaccination after hearing about the painful side effects from the vaccinated people.…”

Section: Resultsmentioning

confidence: 99%

“…Furthermore, since only Comirnaty™ was provided at the vaccination site in this study, comments from people who had taken other vaccines were not available. Although the side effects reported for each vaccine were different, the incidence rate of side effects did not differ significantly for any COVID-19 vaccines, so the influence on the results of this study was considered to be minimal[26].…”

Section: Discussionmentioning

confidence: 99%

A Qualitative Study Regarding Messages of the COVID-19 Vaccine from Vaccinated Healthcare Providers and Healthy Adults

Sano

Sato

Ohmagari

et al. 2022

Preprint

View full text Add to dashboard Cite

1.AbstractBackgroundTo promote the vaccination against COVID-19, person-to-person communication from vaccinated people will play an important role. The objectives of this study are to identify what messages were shared by vaccinated people, and the relationship between these messages and their background.MethodsThis study was an exploratory and prospective basis with individual interviews. The participants were healthcare providers and healthy adults who were recruited at a vaccination site in Chuo-City, Tokyo. The online interviews were conducted using a semi-structured interview. Based on the Health Belief Model (HBM), the participants were asked about their perspectives on vaccines and what they talked about after their vaccination. The interviews were categorized into each item of the HBM and analyzed using NVivo software.ResultsDuring August to October 2021, five healthcare providers and seven healthy adults were enrolled in the study. One healthy adult could not be contacted resulting in a total of 11 participants interviewed. Both the healthcare providers and the healthy adults mainly talked about side effects after their vaccination, and to ease the other persons’ concerns based on their experience. Meanwhile, there were differences in the recommendations for vaccination between the two groups. The healthcare providers were strongly aware of the severity of COVID-19 infection and recommended vaccination to others as a useful measure to suppress becoming severely ill. On the other hand, the healthy adults recommended the vaccine with varying degree depending on their expectations and concerns about the vaccine and external factors such as living with a family member.ConclusionBoth the healthcare providers and healthy adults shared similar messages to ease the vaccination concerns of others. However, their vaccine recommendation level was varied, which may be influenced not only by expectations and concerns toward the vaccine, but also by external factors such as family members living together.

show abstract

“…Research on the efficacy and safety of vaccines is still in progress. 4 5 6 7 The short-term adverse effects of the vaccine are not significantly different from those of other vaccines, and long-term adverse effects are not yet known. Moreover, in patients with rare adverse effects, it is difficult to evaluate the causal relationship with the vaccine.…”

Section: Introductionmentioning

confidence: 99%

Microscopic Polyangiitis Following mRNA COVID-19 Vaccination: A Case Report

Min

Jung

et al. 2022

J Korean Med Sci

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is one of the most widespread viral infections in human history. As a breakthrough against infection, vaccines have been developed to achieve herd immunity. Here, we report the first case of microscopic polyangiitis (MPA) following BNT162b2 vaccination in Korea. A 42-year-old man presented to the emergency room with general weakness, dyspnea, and edema after the second BNT162b2 vaccination. He had no medical history other than being treated for tuberculosis last year. Although his renal function was normal at last year, acute kidney injury was confirmed at the time of admission to the emergency room. His serum creatinine was 3.05 mg/dL. Routine urinalysis revealed proteinuria (3+) and hematuria. When additional tests were performed for suspected glomerulonephritis, the elevation of myeloperoxidase (MPO) antibody (38.6 IU/mL) was confirmed. Renal biopsy confirmed pauci-immune anti-neutrophil cytoplasmic antibody (ANCA)-related glomerulonephritis and MPA was diagnosed finally. As an induction therapy, a combination of glucocorticoid and rituximab was administered, and plasmapheresis was performed twice. He was discharged after the induction therapy and admitted to the outpatient clinic 34 days after induction therapy. During outpatient examination, his renal function had improved with serum creatinine 1.51 mg/dL. We suggest that MPA needs to be considered if patients have acute kidney injury, proteinuria, and hematuria after vaccination.

show abstract

Comparison of constitutional and dermatologic side effects between COVID-19 and non–COVID-19 vaccines: Review of a publicly available database of vaccine side effects

Cited by 6 publications

References 3 publications

Oral Adverse Events Following COVID-19 Vaccination: Analysis of VAERS Reports

Oral Adverse Events Following COVID-19 Vaccination: Analysis of VAERS Reports

A Qualitative Study Regarding Messages of the COVID-19 Vaccine from Vaccinated Healthcare Providers and Healthy Adults

Microscopic Polyangiitis Following mRNA COVID-19 Vaccination: A Case Report

Contact Info

Product

Resources

About